Survival analysis of HDR brachytherapy versus reoperation versus temozolomide alone: A retrospective cohort analysis of recurrent glioblastoma multiforme

BMJ Open

Volumn 3, Issue 3, 2013, Pages

  Archavlis, Eleftherios ^a   Tselis, Nikolaos ^a   Birn, Gerhard ^a   Ulrich, Peter ^a   Baltas, Dimos ^a   Zamboglou, Nikolaos ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MANNITOL; TEMOZOLOMIDE;

ADULT; ANOREXIA; ARTICLE; BACTERIAL MENINGITIS; BRACHYTHERAPY; BRAIN HEMORRHAGE; CANCER GROWTH; CHEMORADIOTHERAPY; CONSERVATIVE TREATMENT; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLIOBLASTOMA; HIGH DOSE RATE BRACHYTHERAPY; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PNEUMOCYSTIS PNEUMONIA; PRIMARY MEDICAL CARE; PROGRESSION FREE SURVIVAL; RADIATION INDUCED EMESIS; RADIATION NECROSIS; RADIATION SICKNESS; RECURRENT CANCER; REOPERATION; RETROSPECTIVE STUDY; SALVAGE THERAPY; SIDE EFFECT; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 84877649593     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-002262     Document Type: Article

References (33)

1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008;359:492-507.
2. Affronti ML, Heery CR, Herndon JE II, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer 2009;115:3501-11.
3. Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Curr Treat Options Neurol 2010;12:321-33.
4. Trent S, Kong A, Short SC, et al. Temozolomide as second-line chemotherapy for relapsed gliomas. J Neurooncol 2002; 57:247-51. (Pubitemid 34692633)
5. Taal W, Segers-van Rijn JM, Kros JM, et al. Dose dense 1 week on/1 week off temozolomide in recurrent glioma: A retrospective study. J Neurooncol 2012;108:195-200.
6. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
7. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol 2010;28:3838-43.
8. Höllerhage HG, Zumkeller M, Becker M, et al. Influence of type and extent of surgery on early results and survival time in glioblastoma multiforme. Acta Neurochir (Wien) 1991;113:31-7.
9. Gerstein J, Franz K, Steinbach JP, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010;97:382-6.
10. Ammirati M, Galicich JH, Arbit E, et al. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 1987;21:607-14. (Pubitemid 18001496)
11. Barker FG II, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery 1998;42:709-20.
12. Dirks P, Bernstein M, Muller PJ, et al. The value of reoperation for recurrent glioblastoma. Can J Surg 1993;36:271-5. (Pubitemid 23248140)
13. Harsh GR IV, Levin VA, Gutin PH, et al. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 1987;21:615-21. (Pubitemid 18001497)
14. Tselis N, Kolotas C, Birn G, et al. CT-guided interstitial HDR brachytherapy for recurrent glioblastoma multiforme. Long-term results. Strahlenther Onkol 2007;183:563-70. (Pubitemid 47482157)
15. Kolotas C, Birn G, Baltas D, et al. CT guided interstitial high dose rate brachytherapy for recurrent malignant gliomas. Br J Radiol 1999;72:805-8. (Pubitemid 29387041)
16. Wick W, Steinbach JP, Küker WM, et al. One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004;62:2113-15. (Pubitemid 38738235)
17. Gállego Pérez-Larraya J, Lahutte M, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: Comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 2012;14:667-73.
18. Choucair AK, Levin VA, Gutin PH, et al. Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 1986;65:654-8. (Pubitemid 17177515)
19. Phuphanich S, Ferrall S, Greenberg H. Long-term survival in malignant glioma. Prognostic factors. J Fla Med Assoc 1993;80:181-4. (Pubitemid 23140542)
20. Boiardi A. PCV chemotherapy for recurrent glioblastoma multiforme. Neurology 2001;56:1782. (Pubitemid 32574594)
21. Newlands ES, Foster T, Zaknoen S. Phase I study of temozolamide (TMZ) combined with procarbazine (PCB) in patients with gliomas. Br J Cancer 2003;89:248-51. (Pubitemid 36976310)
22. Gutin PH, Leibel SA, Wara WM, et al. Recurrent malignant gliomas: Survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 1987;67:864-73. (Pubitemid 18005532)
23. Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: Long-term results in 172 patients treated in a single institution. J Clin Oncol 2005;23:8863-9. (Pubitemid 46211533)
24. Villavicencio AT, Burneikiene S, Romanelli P, et al. Survival following stereotactic radiosurgery for newly diagnosed and recurrent glioblastoma multiforme: A multicenter experience. Neurosurg Rev 2009;32:417-24.
25. Combs SE, Debus J, Schulz-Ertner D. Radiotherapeutic alternatives for previously irradiated recurrent gliomas. BMC Cancer 2007;7:167.
26. Shaw E, Scott C, Souhami L, et al. Radiosurgery for the treatment of previously irradiated recurrent primary brain tumors and brain metastases: Initial report of radiation therapy oncology group protocol (90-05). Int J Radiat Oncol Biol Phys 1996;34:647-54. (Pubitemid 26069194)
27. Leibel SA, Gutin PH, Wara WM, et al. Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989;17:1129-39. (Pubitemid 20028628)
28. Scharfen CO, Sneed PK, Wara WM, et al. High activity iodine-125 interstitial implant for gliomas. Int J Radiat Oncol Biol Phys 1992;24:583-91.
29. Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas: A beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol 2009;185:235-40.
30. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 2010;98:93-9.
31. Terasaki M, Shibui S, Narita Y, et al. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen-A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 2011;29:337-44.
32. Moviglia GA, Carrizo AG, Varela G, et al. Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme. Hematol Oncol Stem Cell Ther 2008;1:3-13.
33. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27:740-5.